Skip to content

BMY vs MRK: Dividend Comparison

BMY$60.77
Bristol Myers Squibb Co
Health Care
vs
MRK$143.37
Merck & Co., Inc.
Health Care

Dividend data as of

Bristol Myers Squibb Co (BMY) and Merck & Co., Inc. (MRK) are both in the Health Care sector, making them natural rivals for dividend investors. BMY offers a significantly higher 4.00% yield compared to MRK's 2.33%, a gap of 1.67%. Both stocks show similar dividend growth rates, each around 5.1% over the past five years. Both stocks carry a "Safe" dividend safety rating. Both are classified as Dividend Contenders.

Verdict

Best for Income
BMY
Higher yield at 4.00%
Best for Growth
MRK
5yr CAGR of 6.0%
Best for Safety
MRK
Lower payout ratio (3%)

Track BMY and MRK in your portfolio

See your real income from both — forward projections, yield on cost, and dividend safety signals. Sync your brokerage free for 30 days, or track holdings manually on the free plan (1 portfolio, 10 holdings).

30-day free brokerage sync trial. No credit card. Then from $9.99/month. Choosing a tracker? See the best dividend trackers compared.

Metric
Price
$60.77
$143.37
Dividend Yield
4.00%
2.33%
Annual Dividend
$2.52
$3.40
5yr Div CAGR
5.1%
6.0%
3yr Div CAGR
3.4%
5.2%
Consecutive Years
18
15
Payout Ratio
55.88%
3.43%
P/E Ratio
—
—
Market Cap
—
—
Income on $10k
$400/yr
$233/yr

Yield Analysis

BMY
4.00%
MRK
2.33%

BMY yields 1.67% more than MRK. In dollar terms, BMY pays $2.52/share vs MRK's $3.40/share annually.

Dividend Growth

BMY 5yr CAGR
5.1%
decelerating
MRK 5yr CAGR
6.0%
decelerating

BMY: Dividend growth is slowing — the 3-year CAGR of 3.4% trails the 5-year rate of 5.1% and the 10-year rate of 5.2%.

MRK: Dividend growth is slowing — the 3-year CAGR of 5.2% trails the 5-year rate of 6.0% and the 10-year rate of 6.8%.

Dividend Safety

BMY
Safe
Payout Ratio56%
MRK
Safe
Payout Ratio3%

BMY: The payout ratio of 56% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 1.8x.

MRK: The payout ratio of 3% is well within sustainable levels, leaving room for future increases. Earnings cover the dividend 0.3x.

Estimated Annual Dividend Income

Based on current dividend yields. Actual income may vary.

Investment
BMY
MRK
$10,000
$400/yr
$233/yr
$50,000
$2,002/yr
$1,167/yr
$100,000
$4,004/yr
$2,333/yr

What does $10,000 buy in BMY vs MRK today?

At $60.77 per share, $10,000 buys about 164.6 shares of Bristol Myers Squibb Co (BMY). Each share pays $2.52 per year in dividends, so the position starts out generating roughly $415 per year — about $35 a month.

At $143.37 per share, $10,000 buys about 69.7 shares of Merck & Co., Inc. (MRK). Each share pays $3.40 per year in dividends, so the position starts out generating roughly $237 per year — about $20 a month.

BMY is the larger income stream from day one: $178 per year more on the same $10,000 invested.

What could $10,000 of BMY or MRK income look like in 10 years?

Bristol Myers Squibb Co (BMY) has raised its dividend about 5.1% a year over the past five years. If that pace held, the $400 per year that $10,000 generates today at the current 4.00% yield would reach $662 per year by 2036 — a 6.6% yield on the original cost.

Merck & Co., Inc. (MRK) has raised its dividend about 6.0% a year over the past five years. If that pace held, the $233 per year that $10,000 generates today at the current 2.33% yield would reach $418 per year by 2036 — a 4.2% yield on the original cost.

On those trailing rates, BMY pays more in 2036: $662 versus $418 per year. The projection assumes each five-year growth rate persists and no dividends are reinvested — real payouts will differ.

When would MRK's dividend growth overtake BMY's higher yield?

Not within a realistic holding period. Merck & Co., Inc. (MRK) is growing its dividend faster (6.0% vs 5.1% a year), but the starting-yield gap — 4.00% for BMY vs 2.33% for MRK — is wide enough that the crossover sits more than 30 years out on trailing rates. For income you plan to spend, BMY's head start is decisive.

Can BMY and MRK afford their dividends?

Bristol Myers Squibb Co (BMY) earns $4.51 per share against $2.52 paid out in dividends — 1.8x coverage (a 56% payout ratio).

Merck & Co., Inc. (MRK) earns $1.00 per share against $3.40 paid out in dividends — 0.3x coverage (a 3% payout ratio).

BMY's wider coverage leaves more cushion if earnings dip. As a rule of thumb, coverage below about 1.5x (a payout ratio above ~65%) is where a dividend starts to look stretched — worth watching for MRK if earnings weaken.

Which fits an early-retirement income portfolio better, BMY or MRK?

For income you need right now, Bristol Myers Squibb Co (BMY) leads: $100,000 invested today pays about $334 a month at the current 4.00% yield, versus $194 a month from Merck & Co., Inc. (MRK) at 2.33%.

With a decade or more before the income is needed, MRK's faster dividend growth (6.0% vs 5.1% a year) matters more than the starting yield — raises compound into the larger paycheck over time.

On consistency: BMY has raised its dividend 18 consecutive years; MRK has raised its dividend 15 consecutive years.

Many income investors simply hold both — the mix pairs current yield with growth and spreads single-name risk. Whichever way you lean, dividends are never guaranteed; recheck the payout each quarter rather than setting and forgetting.

$10,000 with DRIP: projected annual income

If each holding keeps raising its dividend at its real 5-year rate and every payment is reinvested, a $10,000 position pays $980/yr in BMY vs $526/yr in MRK by year 10.

Assumes dividends are reinvested at the current yield and grow at each holding's trailing 5-year dividend CAGR. A projection, not a prediction — no price appreciation modeled.

Frequently Asked Questions

This tool is for educational and informational purposes only and does not constitute investment, financial, tax, or legal advice. Consult a licensed professional before making investment decisions.

Past performance does not guarantee future results. All projections are hypothetical estimates based on user-provided inputs and may differ materially from actual outcomes.

By using this tool you agree to our Terms of Service and Privacy Policy.